Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 9, 2012, Pages 5877-5880

  Kakinoki, Masashi ^a   Sawada, Osamu ^a   Sawada, Tomoko ^a   Saishin, Yoshitsugu ^a   Kawamura, Hajime ^a   Ohji, Masahito ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CILIARY DISK; CONTROLLED STUDY; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; MACACA; MALE; NONHUMAN; PRIORITY JOURNAL; VITRECTOMY; VITREOUS BODY; ANIMAL; HALF LIFE TIME; INTRAVITREAL DRUG ADMINISTRATION; MACACA FASCICULARIS; METABOLISM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUEOUS HUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; INTRAVITREAL INJECTIONS; MACACA FASCICULARIS; MALE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY;

EID: 84871683928     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10164     Document Type: Article

References (16)

1. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005; 112:1035-1047.
2. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology. 2006;113: 2002-2011.
3. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695-1705.
4. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26:275-278.
5. Sawada O, Kawamura H, Kakinoki M, Ohji M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol. 2007;125:1363-1366.
6. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina. 2006;26:383-390.
7. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:336-339.
8. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006;26: 279-284.
9. Miyake T, Sawada O, Kakinoki M, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci. 2010;51:1606-1608.
10. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology. 2008;115:1750-1755.
11. Doft BH, Weiskopf J, Nilsson-Ehle I, Wingard LB Jr. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology. 1985;92:1601-1605.
12. Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 2005;25:556-560.
13. Lee SS, Ghosn C, Yu Z, et al. Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci. 2010; 51:2135-2138.
14. Yamamoto T, Hitani K, Tsukahara I, et al. Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macular edema. Am J Ophthalmol. 2003;135:14-19.
15. Yanyali A, Horozoglu F, Celik E, Nohutcu AF. Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina. 2007; 27:557-566.
16. Hartly KL, Smiddy WE, Flynn HW Jr, Murray TG. Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina. 2008;28:410-419.